Esperion Therapeutics (ESPR) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

ESPR Stock Forecast

Esperion Therapeutics stock forecast is as follows: an average price target of $8.00 (represents a 268.66% upside from ESPR’s last price of $2.17) and a rating consensus of 'Buy', based on 9 wall street analysts offering a 1-year stock forecast.

ESPR Price Target

The average price target for Esperion Therapeutics (ESPR) is $8.00 based on 1-year price targets from 9 Wall Street analysts in the past 3 months, with a price target range of $8.00 to $8.00. This represents a potential 268.66% upside from ESPR's last price of $2.17.

ESPR Analyst Ratings

Buy

According to 9 Wall Street analysts, Esperion Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for ESPR stock is 0 'Strong Buy' (0.00%), 7 'Buy' (77.78%), 2 'Hold' (22.22%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Esperion Therapeutics Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Dec 17, 2024	Kristen Kluska	Cantor Fitzgerald	$8.00	$3.04	163.16%	268.66%
May 04, 2022	Serge Belanger	Needham	$12.00	$6.53	83.77%	453.00%
May 04, 2021	Derek Archila	Wells Fargo	$20.00	$25.59	-21.84%	821.66%

The latest Esperion Therapeutics stock forecast, released on Dec 17, 2024 by Kristen Kluska from Cantor Fitzgerald, set a price target of $8.00, which represents a 163.16% increase from the stock price at the time of the forecast ($3.04), and a 268.66% increase from ESPR last price ($2.17).

Esperion Therapeutics Price Target by Period

	1M	3M	12M
# Anlaysts	1	1	1
Avg Price Target	$8.00	$8.00	$8.00
Last Closing Price	$2.17	$2.17	$2.17
Upside/Downside	268.66%	268.66%	268.66%

In the current month, the average price target of Esperion Therapeutics stock is $8.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 268.66% increase as opposed to Esperion Therapeutics's last price of $2.17. This month's average price target is down 0.00% compared to last quarter, and down 0.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Dec 17, 2024	Cantor Fitzgerald		Overweight	Initialise
Oct 03, 2024	H.C. Wainwright	Buy	Buy	Hold
Jul 01, 2024	H.C. Wainwright	Buy	Buy	Hold
Jun 20, 2024	Bank of America Securities	Buy	Underperform	Downgrade
May 22, 2024	H.C. Wainwright	Buy	Buy	Hold
Jun 15, 2023	Barclays		Overweight	Initialise
Jun 15, 2023	Guggenheim		Buy	Initialise
Jun 15, 2023	Cowen & Co.		Buy	Upgrade
Jun 15, 2023	Bank of America Securities		Buy	Upgrade
Mar 16, 2023	Needham	Buy	Buy	Hold
Mar 07, 2023	Credit Suisse		Neutral	Upgrade
Feb 03, 2023	Oppenheimer		Outperform	Initialise
Feb 03, 2023	Morgan Stanley		Equal-Weight	Upgrade

Esperion Therapeutics's last stock rating was published by Cantor Fitzgerald on Dec 17, 2024. The company Initialise its ESPR rating from "null" to "Overweight".

Esperion Therapeutics Financial Forecast

Esperion Therapeutics Revenue Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	$33.97M	$25.79M	$24.33M	$18.82M	$18.98M	$18.84M	$18.84M	$15.40M	$14.41M	$40.66M	$7.98M	$9.64M	$3.83M	$212.24M	$1.84M	$982.00K	$981.00K
Avg Forecast	$97.00M	$88.90M	$82.10M	$76.40M	$184.50M	$86.40M	$68.70M	$60.80M	$64.05M	$51.31M	$47.49M	$83.93M	$28.65M	$29.59M	$24.64M	$21.98M	$20.61M	$19.68M	$18.62M	$15.41M	$14.48M	$11.89M	$42.18M	$19.93M	$12.52M	$4.01M	$147.97M	$471.36K	$891.80K	$900.00K
High Forecast	$110.75M	$101.51M	$93.74M	$87.23M	$210.66M	$98.65M	$78.44M	$63.93M	$75.09M	$52.24M	$47.49M	$83.93M	$32.62M	$29.59M	$28.14M	$25.10M	$23.53M	$19.68M	$18.62M	$15.41M	$14.48M	$11.89M	$42.18M	$19.93M	$12.52M	$4.01M	$147.97M	$471.36K	$891.80K	$900.00K
Low Forecast	$88.37M	$80.99M	$74.79M	$69.60M	$168.08M	$78.71M	$62.59M	$58.59M	$52.66M	$50.38M	$47.49M	$83.93M	$22.09M	$29.59M	$22.45M	$20.02M	$18.77M	$19.68M	$18.62M	$15.41M	$14.48M	$11.89M	$42.18M	$19.93M	$12.52M	$4.01M	$147.97M	$471.36K	$891.80K	$900.00K
# Analysts	1	1	1	1	1	1	1	2	5	4	3	3	6	3	3	3	4	4	4	4	3	3	3	3	3	3	3	3	4	4
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	1.15%	1.05%	1.11%	0.91%	0.96%	1.01%	1.22%	1.06%	1.21%	0.96%	0.40%	0.77%	0.96%	1.43%	3.90%	1.10%	1.09%

Esperion Therapeutics's average Quarter revenue forecast for Dec 23 based on 6 analysts is $28.65M, with a low forecast of $22.09M, and a high forecast of $32.62M. ESPR's average Quarter revenue forecast represents a -15.67% decrease compared to the company's last Quarter revenue of $33.97M (Sep 23).

Esperion Therapeutics EBITDA Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	1	1	1	1	1	1	1	2	5	4	3	3	6	3	3	3	4	4	4	4	3	3	3	3	3	3	3	3	4	4
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	$-27.53M	$-37.06M	$-47.33M	$-41.16M	$-40.86M	$-52.06M	$-42.52M	$-51.54M	$-55.58M	$-32.37M	$-82.66M	$-95.39M	$-80.35M	$129.37M	$-73.97M	$-57.72M	$-64.29M
Avg Forecast	$-80.06M	$-73.38M	$-67.76M	$-63.06M	$-152.28M	$-71.31M	$-56.70M	$-50.18M	$-52.86M	$-42.35M	$-39.20M	$-56.89M	$-23.64M	$-24.42M	$-20.34M	$-51.71M	$-69.18M	$-16.26M	$-15.38M	$-47.01M	$-11.96M	$-9.83M	$-34.86M	$-50.51M	$-10.34M	$-3.31M	$-122.26M	$-84.09M	$-736.88K	$-743.65K
High Forecast	$-72.94M	$-66.85M	$-61.73M	$-57.45M	$-138.73M	$-64.97M	$-51.66M	$-48.36M	$-43.46M	$-41.58M	$-39.20M	$-45.51M	$-18.24M	$-24.42M	$-18.53M	$-41.37M	$-55.34M	$-16.26M	$-15.38M	$-37.61M	$-11.96M	$-9.83M	$-34.86M	$-40.41M	$-10.34M	$-3.31M	$-122.26M	$-67.27M	$-736.88K	$-743.65K
Low Forecast	$-91.41M	$-83.78M	$-77.37M	$-72.00M	$-173.87M	$-81.42M	$-64.74M	$-52.77M	$-61.98M	$-43.12M	$-39.20M	$-68.26M	$-26.92M	$-24.42M	$-23.22M	$-62.06M	$-83.01M	$-16.26M	$-15.38M	$-56.42M	$-11.96M	$-9.83M	$-34.86M	$-60.62M	$-10.34M	$-3.31M	$-122.26M	$-100.91M	$-736.88K	$-743.65K
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	1.13%	1.82%	0.92%	0.59%	2.51%	3.38%	0.90%	4.31%	5.66%	0.93%	1.64%	9.22%	24.27%	-1.06%	0.88%	78.33%	86.45%

3 analysts predict ESPR's average Quarter EBITDA for Sep 20 to be $-3.31M, with a high of $-3.31M and a low of $-3.31M. This is -102.56% lower than Esperion Therapeutics's previous annual EBITDA (Jun 20) of $129.37M.

Esperion Therapeutics Net Income Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	1	1	1	1	1	1	1	2	5	4	3	3	6	3	3	3	4	4	4	4	3	3	3	3	3	3	3	3	4	4
Net Income	-	-	-	-	-	-	-	-	-	-	-	-	-	$-41.25M	$-49.94M	$-89.22M	$-68.46M	$-68.61M	$-80.27M	$-70.47M	$-78.55M	$-69.39M	$-43.67M	$-90.94M	$-104.48M	$-85.44M	$124.61M	$-78.25M	$-61.95M	$-68.38M
Avg Forecast	$17.54M	$9.75M	$5.85M	$-23.39M	$75.05M	$-3.90M	$-22.42M	$-32.16M	$-26.97M	$-34.17M	$-33.56M	$-75.90M	$-93.90M	$-83.44M	$-119.18M	$-69.00M	$-87.41M	$-174.65M	$-175.37M	$-62.73M	$-428.43M	$-529.53M	$-348.03M	$-55.57M	$-709.87M	$-665.03M	$310.68M	$-88.95M	$-498.23M	$-368.13M
High Forecast	$20.78M	$11.54M	$6.93M	$-20.69M	$88.88M	$-3.45M	$-19.82M	$-24.12M	$-20.23M	$-30.21M	$-29.67M	$-60.72M	$-70.87M	$-73.79M	$-105.40M	$-55.20M	$-69.93M	$-174.65M	$-175.37M	$-50.19M	$-428.43M	$-529.53M	$-348.03M	$-44.46M	$-709.87M	$-665.03M	$310.68M	$-71.16M	$-498.23M	$-368.13M
Low Forecast	$15.51M	$8.62M	$5.17M	$-27.70M	$66.37M	$-4.62M	$-26.55M	$-42.21M	$-35.96M	$-40.46M	$-39.74M	$-91.09M	$-109.84M	$-98.82M	$-141.15M	$-82.81M	$-104.89M	$-174.65M	$-175.37M	$-75.28M	$-428.43M	$-529.53M	$-348.03M	$-66.69M	$-709.87M	$-665.03M	$310.68M	$-106.74M	$-498.23M	$-368.13M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	0.49%	0.42%	1.29%	0.78%	0.39%	0.46%	1.12%	0.18%	0.13%	0.13%	1.64%	0.15%	0.13%	0.40%	0.88%	0.12%	0.19%

Esperion Therapeutics's average Quarter net income forecast for Sep 20 is $-665.03M, with a range of $-665.03M to $-665.03M. ESPR's average Quarter net income forecast represents a -633.68% decrease compared to the company's last Quarter net income of $124.61M (Jun 20).

Esperion Therapeutics SG&A Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	1	1	1	1	1	1	1	2	5	4	3	3	6	3	3	3	4	4	4	4	3	3	3	3	3	3	3	3	4	4
SG&A	-	-	-	-	-	-	-	-	-	-	-	-	-	$33.24M	$33.96M	$29.90M	$24.14M	$24.95M	$29.61M	$30.38M	$38.34M	$39.27M	$46.32M	$61.06M	$61.55M	$48.83M	$47.68M	$41.55M	$21.71M	$18.47M
Avg Forecast	$123.18M	$112.90M	$104.26M	$97.02M	$234.30M	$109.72M	$87.24M	$77.21M	$81.34M	$65.16M	$60.31M	$40.65M	$36.38M	$37.57M	$31.30M	$27.91M	$26.17M	$24.99M	$23.64M	$19.56M	$18.38M	$15.10M	$53.56M	$25.31M	$15.90M	$5.09M	$187.87M	$598.46K	$1.13M	$1.14M
High Forecast	$140.65M	$128.90M	$119.04M	$110.78M	$267.52M	$125.28M	$99.61M	$81.19M	$95.36M	$66.34M	$60.31M	$48.78M	$41.42M	$37.57M	$35.73M	$31.87M	$29.88M	$24.99M	$23.64M	$19.56M	$18.38M	$15.10M	$53.56M	$25.31M	$15.90M	$5.09M	$187.87M	$598.46K	$1.13M	$1.14M
Low Forecast	$112.22M	$102.85M	$94.98M	$88.39M	$213.45M	$99.96M	$79.48M	$74.41M	$66.87M	$63.98M	$60.31M	$32.52M	$28.06M	$37.57M	$28.51M	$25.43M	$23.84M	$24.99M	$23.64M	$19.56M	$18.38M	$15.10M	$53.56M	$25.31M	$15.90M	$5.09M	$187.87M	$598.46K	$1.13M	$1.14M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	0.88%	1.09%	1.07%	0.92%	1.00%	1.25%	1.55%	2.09%	2.60%	0.86%	2.41%	3.87%	9.60%	0.25%	69.43%	19.18%	16.16%

Esperion Therapeutics's average Quarter SG&A projection for Dec 23 is $36.38M, based on 6 Wall Street analysts, with a range of $28.06M to $41.42M. The forecast indicates a 9.44% rise compared to ESPR last annual SG&A of $33.24M (Sep 23).

Esperion Therapeutics EPS Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	1	1	1	1	1	1	1	2	5	4	3	3	6	3	3	3	4	4	4	4	3	3	3	3	3	3	3	3	4	4
EPS	-	-	-	-	-	-	-	-	-	-	-	-	-	$-0.37	$-0.00	$-1.14	$-0.93	$-1.01	$-1.27	$-1.16	$-2.13	$-2.62	$-1.67	$-3.50	$-3.89	$-3.07	$4.50	$-2.84	$-2.26	$-2.52
Avg Forecast	$0.09	$0.05	$0.03	$-0.12	$0.39	$-0.02	$-0.12	$-0.17	$-0.14	$-0.18	$-0.17	$0.05	$-0.48	$-0.43	$-0.61	$-0.65	$-0.85	$-0.93	$-0.93	$-1.04	$-2.27	$-2.80	$-1.84	$-2.52	$-3.76	$-3.52	$1.65	$-3.30	$-2.64	$-1.95
High Forecast	$0.11	$0.06	$0.04	$-0.11	$0.46	$-0.02	$-0.10	$-0.12	$-0.10	$-0.15	$-0.15	$0.05	$-0.36	$-0.38	$-0.54	$-0.58	$-0.75	$-0.93	$-0.93	$-1.04	$-2.27	$-2.80	$-1.84	$-2.52	$-3.76	$-3.52	$1.65	$-3.30	$-2.64	$-1.95
Low Forecast	$0.08	$0.04	$0.03	$-0.14	$0.34	$-0.02	$-0.14	$-0.22	$-0.18	$-0.21	$-0.20	$0.05	$-0.56	$-0.51	$-0.72	$-0.77	$-1.00	$-0.93	$-0.93	$-1.04	$-2.27	$-2.80	$-1.84	$-2.52	$-3.76	$-3.52	$1.65	$-3.30	$-2.64	$-1.95
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	0.86%	0.00%	1.75%	1.10%	1.09%	1.37%	1.12%	0.94%	0.93%	0.91%	1.39%	1.03%	0.87%	2.73%	0.86%	0.86%	1.29%

According to 3 Wall Street analysts, Esperion Therapeutics's projected average Quarter EPS for Sep 20 is $-3.52, with a low estimate of $-3.52 and a high estimate of $-3.52. This represents a -178.28% decrease compared to ESPR previous annual EPS of $4.50 (Jun 20).

Esperion Therapeutics Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
RMTI	Rockwell Medical	$2.22	$9.00	305.41%	Buy
KMDA	Kamada	$5.75	$20.00	247.83%
ESPR	Esperion Therapeutics	$2.46	$8.00	225.20%	Buy
AVDL	Avadel Pharmaceuticals	$10.73	$30.00	179.59%	Buy
IRWD	Ironwood Pharmaceuticals	$3.53	$8.50	140.79%	Buy
ELAN	Elanco Animal Health	$12.31	$17.50	42.16%	Buy
ANIP	ANI Pharmaceuticals	$55.83	$79.00	41.50%	Buy
COLL	Collegium Pharmaceutical	$30.90	$42.33	36.99%	Buy
ALKS	Alkermes	$30.75	$37.50	21.95%	Hold
PCRX	Pacira BioSciences	$19.83	$23.75	19.77%	Hold
NBIX	Neurocrine Biosciences	$136.69	$156.14	14.23%	Buy
PBH	Prestige Consumer Healthcare	$80.39	$89.50	11.33%	Buy
ITCI	Intra-Cellular Therapies	$86.96	$93.33	7.33%	Buy
CTLT	Catalent	$63.48	$63.50	0.03%	Hold
LFCR	Lifecore Biomedical	$7.47	$6.50	-12.99%	Buy
PAHC	Phibro Animal Health	$22.34	$18.67	-16.43%	Buy

ESPR Forecast FAQ

Is Esperion Therapeutics a good buy?

Yes, according to 9 Wall Street analysts, Esperion Therapeutics (ESPR) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 7 'Buy' recommendations, accounting for 77.78% of ESPR's total ratings.

What is ESPR's price target?

Esperion Therapeutics (ESPR) average price target is $8 with a range of $8 to $8, implying a 268.66% from its last price of $2.17. The data is based on 9 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Esperion Therapeutics stock go up soon?

According to Wall Street analysts' prediction for ESPR stock, the company can go up by 268.66% (from the last price of $2.17 to the average price target of $8), up by 268.66% based on the highest stock price target, and up by 268.66% based on the lowest stock price target.

Can Esperion Therapeutics stock reach $3?

ESPR's average twelve months analyst stock price target of $8 supports the claim that Esperion Therapeutics can reach $3 in the near future.

What is Esperion Therapeutics's current price target trend?

1 Wall Street analyst forecast a $8 price target for Esperion Therapeutics (ESPR) this month, up 268.66% from its last price of $2.17. Compared to the last 3 and 12 months, the average price target increased by 268.66% and increased by 268.66%, respectively.

What are Esperion Therapeutics's analysts' financial forecasts?

Esperion Therapeutics's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $400.4M (high $451.68M, low $367.97M), average EBITDA is $-330M (high $-304M, low $-373M), average net income is $16.57M (high $41.49M, low $-7.015M), average SG&A $508.48M (high $573.6M, low $467.29M), and average EPS is $0.085 (high $0.213, low $-0.036). ESPR's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $344.4M (high $393.23M, low $313.75M), average EBITDA is $-284M (high $-259M, low $-325M), average net income is $9.75M (high $18.56M, low $1.6M), average SG&A $437.36M (high $499.37M, low $398.44M), and average EPS is $0.05 (high $0.0952, low $0.00821).

Did the ESPR's actual financial results beat the analysts' financial forecasts?

Based on Esperion Therapeutics's last annual report (Dec 2023), the company's revenue was $116.33M, beating the average analysts forecast of $104.86M by 10.95%. Apple's EBITDA was $-156M, beating the average prediction of $-120M by 29.51%. The company's net income was $-209M, missing the average estimation of $-366M by -42.75%. Apple's SG&A was $142.52M, beating the average forecast of $133.16M by 7.03%. Lastly, the company's EPS was $-0.002, missing the average prediction of $-2.173 by -99.91%. In terms of the last quarterly report (Sep 2023), Esperion Therapeutics's revenue was $33.97M, beating the average analysts' forecast of $29.59M by 14.81%. The company's EBITDA was $-27.533M, beating the average prediction of $-24.42M by 12.75%. Esperion Therapeutics's net income was $-41.25M, missing the average estimation of $-83.442M by -50.56%. The company's SG&A was $33.24M, missing the average forecast of $37.57M by -11.53%. Lastly, the company's EPS was $-0.37, missing the average prediction of $-0.428 by -13.56%